How effective is ixazomib in the treatment of patients with multiple myeloma? clinical research analysis

Ixazomib (Ixazomib) is one of the oral proteasome inhibitors that has developed rapidly in recent years and is mainly used for the treatment of multiple myeloma (MM). As the first oral form of proteasome inhibitor, ixazomib provides patients with a more convenient administration method, and its efficacy and safety are also supported by multiple clinical studies. In the treatment of multiple myeloma, ixazomib is often combined with lenalidomide (Lenalidomide) and dexamethasone (Dexamethasone pan>) combined to form a standard triple therapy (IRd regimen), which is especially suitable for relapsed/refractory patients.

First of all, from the perspective of efficacy, the clinical application effect of ixazomib has shown good data support in multiple international studies. The most representative study is a phase III clinical trial called TOURMALINE-MM1. The trial enrolled 722 patients with relapsed or refractory multiple myeloma and compared the IRd regimen (ixazomib + ixazomib span>Lenalidomide+dexamethasone) and placebo+lenalidomide+dexamethasone. The results of the study show that the median progression-free survival (PFS) of patients who received the IRd regimen reached 20 .6 months, while the control group was only 14.7 months, an extension of about 6 months, and the difference was statistically significant. In addition, in terms of response rate, the overall response rate in the IRd group exceeded 78%, including a complete response rate of approximately 12%.

Secondly, performance among specific groups of people is also worthy of attention. Studies have shown that ixazomib also has certain efficacy in patients with high-risk chromosomal abnormalities (such as del(17p), t(4;14), etc.). Although high-risk patients have a poor overall prognosis,IRdThe progression-free survival of the program in this population is still significantly better than that of the control group, suggesting that ixazomib has potential disease control capabilities. In addition, because it is an oral drug, it can effectively reduce the frequency of patient visits, avoid the inconvenience caused by long-term intravenous infusion, and improve patient compliance and quality of life.

In terms of safety, ixazomib was generally well tolerated. Common adverse reactions include gastrointestinal reactions (such as nausea, vomiting, diarrhea), fatigue, rash, thrombocytopenia, and peripheral neuropathy. However, ixazomib is associated with a lower incidence of severe neurotoxicity than conventional bortezomib. In the TOURMALINE-MM1 study, the incidence of grade 3 and above neuropathy was less than 2%, which is particularly important for long-term maintenance treatment. In addition, the dosage adjustment of ixazomib is relatively flexible, and can be appropriately adjusted for patients of different ages and liver and kidney function status to ensure safety.

It is worth noting that the study of ixazomib in treatment-naïve patients is also continuing to advance. There are currently some studies exploring the possibility of combining it with other drugs, such as combining it with new drugs such as Daratumumab and Pomalidomide to further improve the response rate and prolong survival. At the same time, the application of maintenance therapy is also increasing, and some studies support its ability to prolong disease control time and delay recurrence during maintenance therapy after first remission.

In summary, ixazomib has demonstrated good efficacy and acceptable safety in the treatment of multiple myeloma, especially in relapsed/refractory patients. Its oral dosage form brings greater convenience to patients and provides new ideas for long-term treatment. As more clinical studies advance, ixazomib is expected to play a greater role in initial treatment, maintenance and combination therapy, providing more comprehensive treatment options for myeloma patients.

Reference materials:https://www.ninlaro.com/